
ANRO Stock Forecast & Price Target
ANRO Analyst Ratings
Bulls say
Alto Neuroscience is at an inflection point with the initiation of their Phase 2B study for ALTO-207 in TRD, with potential regulatory filings by 2028. However, there are commercial risks with market acceptance, financial risks with the need for additional capital, and potential regulatory risks with the use of accelerated strategies and reliance on third parties for clinical studies. Overall, the potential for personalized and effective treatments in the psychiatric market is promising, but caution should be taken with the associated risks.
Bears say
Alto Neuroscience is a clinical-stage biopharmaceutical company with a high level of financial risk due to the need for additional capital before becoming profitable and potential dilution for shareholders. The company also faces intellectual property risks and uncertainty with their unproven biomarker approach for precision medicines. Additionally, their drug candidates are in various stages of development, and clinical trials in depression have high failure rates, which could negatively impact the company's valuation.
This aggregate rating is based on analysts' research of Alto Neuroscience Inc and is not a guaranteed prediction by Public.com or investment advice.
ANRO Analyst Forecast & Price Prediction
Start investing in ANRO
Order type
Buy in
Order amount
Est. shares
0 shares